The U.S. Food and Drug Administration has approved a new mRNA-based seasonal flu vaccine for people 50 and older, Moderna ...
Moderna began a Phase 1 clinical trial of its experimental vaccine mRNA-1469 targeting the Bundibugyo strain of Ebola virus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results